List of Tables
Table 1: Rheumatic Disorders Drugs Market, Global, Etiology of RA, OA, Osteoporosis, SLE and PsA, 2018
Table 2: Rheumatic Disorders Drugs Market, 7MM, Epidemiology of Key Rheumatic Disorders Indications, 2018
Table 3: Rheumatic Disorders Drugs Market, Global, Overview of the Treatments for Different Patient Segments within RA, 2018
Table 4: Rheumatic Disorders Drugs Market, Global, Off-label Treatments for RA, 2018
Table 5: Rheumatic Disorders Drugs Market, Global, Overview of the Treatments for Different Patient Segments within OA, 2018
Table 6: Rheumatic Disorders Drugs Market, Global, Off-label Treatments for OA, 2018
Table 7: Rheumatic Disorders Drugs Market, Global, Overview of the Treatments for Different Patient Segments within Osteoporosis, 2018
Table 8: Rheumatic Disorders Drugs Market, Global, Off-label Treatments for Osteoporosis, 2018
Table 9: Rheumatic Disorders Drugs Market, Global, Overview of the Treatments for Different Patient Segments within SLE, 2018
Table 10: Rheumatic Disorders Drugs Market, Global, Off-label Treatments for SLE, 2018
Table 11: Rheumatic Disorders Drugs Market, Global, Overview of the Treatments for Different Patient Segments within PsA, 2018
Table 12: Rheumatic Disorders Drugs Market, Global, Off-label Treatments for PsA, 2018
Table 13:Rheumatic Disorders Drugs Market, Global, Key Marketed Products Overview, 2018
Table 14: Rheumatic Disorders Drugs Market, Global, Approved Rheumatic Disorders Indications for Humira, 2018
Table 15: Rheumatic Disorders Drugs Market, Global, Approved Rheumatic Disorders Indications for Enbrel, 2018
Table 16: Rheumatic Disorders Drugs Market, Global, Rheumatic Disorders Indications that have been Approved or are in Late-Stage Development for Simponi, 2018
Table 17: Rheumatic Disorders Drugs Market, Global, Approved Rheumatic Disorders Indications for Remicade, 2018
Table 18: Rheumatic Disorders Drugs Market, Global, Approved Rheumatic Disorders Indications for Rituxan, 2018
Table 19: Rheumatic Disorders Drugs Market, Global, Rheumatic Disorders Indications that have been Approved or are in Late-Stage Development for Stelara, 2018
Table 20: Rheumatic Disorders Drugs Market, Global, Rheumatic Disorders Indications that have been Approved or are in Late-Stage Development for Cosentyx, 2018
Table 21: Rheumatic Disorders Drugs Market, Global, Approved Rheumatic Disorders Indications for Prolia, 2018
Table 22: Rheumatic Disorders Drugs Market, Global, Rheumatic Disorders Indications that have been Approved or are in Late-Stage Development for Orencia, 2018
Table 23: Rheumatic Disorders Drugs Market, Global, Approved Rheumatic Disorders Indications for Actemra, 2018
Table 24: Rheumatic Disorders Drugs Market, Global, Rheumatic Disorders Indications that have been Approved or are in Late-Stage Development for Benlysta, 2018
Table 25: Rheumatic Disorders Drugs Market, Global, Approved Rheumatic Disorders Indications for Forteo, 2018
Table 26: Rheumatic Disorders Drugs Market, Global, Annual Revenue Forecast for Key Products ($m), 2017–2024
Table 27: Rheumatic Disorders Drugs Market, Global, Use of Generics Across Key Indications, 2018
Table 28: Rheumatic Disorders Drugs Market, Global, Forecast Revenue by Company (%), 2017–2024